Form 4: Pfizer CEO Albert Bourla Acquires Additional Phantom Stock Units
Insider Transaction Report
Pfizer's Chairman and CEO, Albert Bourla, acquired 25 phantom stock units on June 30, 2025, increasing his total beneficial ownership to 718,220 units.
Summary
- Albert Bourla, Chairman and CEO of Pfizer Inc., acquired 25 phantom stock units.
- The transaction occurred on June 30, 2025.
- Each phantom unit represents one phantom share of Pfizer common stock.
- The acquisition price for these units was $24.24 per unit.
- Following this transaction, Mr. Bourla beneficially owns a total of 718,220 phantom stock units.
- These units were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
- The phantom stock units are settled in cash upon the reporting person's separation from service and can be transferred into an alternative investment account at any time.
Sentiment
Score: 6
Explanation: The acquisition of additional phantom stock units by the CEO, while a small number relative to total holdings, generally indicates continued alignment of management interests with shareholder value, though the units are cash-settled upon separation.
Positives
- Chairman and CEO Albert Bourla increased his beneficial ownership of phantom stock units, which can be interpreted as a sign of continued confidence in Pfizer's future performance and alignment with shareholder interests.
Future Outlook
No forward-looking statements or guidance regarding company performance or strategic direction are provided in this transaction report.
Management Comments
- Each unit represents one phantom share of common stock.
- These units, acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Industry Context
This Form 4 filing reports an individual executive's compensation-related transaction and does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders: May view the CEO's acquisition of additional phantom stock units as a positive signal of management's confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of transaction for the acquisition of phantom stock units by Albert Bourla. |
| 07/02/2025 | Date the Form 4 filing was signed by power of attorney for Albert Bourla. |
Keywords
Pfizer, PFE, Albert Bourla, Insider Transaction, Form 4, Phantom Stock Units, Executive Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.